###### Strengths and limitations of this study

-   This is the first study to examine the relation between a disorder with the potential to disrupt sleep on a chronic basis (benign prostatic hyperplasia (BPH)) and motor neuron disease (MND).

-   The exposure (BPH) and outcome (MND) were determined from nationwide, population-based, linked medical registries in a country with national health service and universal access to care.

-   The long follow-up and large sample size allow longer exposure, reduce concerns of reverse causality and increase precision of the results.

-   The validity of the diagnosis of BPH in this population is not known; some men diagnosed with BPH may not have sleep disruption due to nocturia; some men in the general population comparison cohort may have had undiagnosed BPH; and some men diagnosed with MND may have had a different disorder.

-   Our analyses were adjusted for factors associated with both BPH and MND, but results could have been affected by unrecognised confounding.

Introduction {#s1}
============

Motor neuron disease (MND) includes amyotrophic lateral sclerosis (ALS) and closely related disorders such as progressive bulbar palsy. These are progressive neurodegenerative diseases that affect motor neurons in the spinal cord, brainstem and cerebrum.[@R1] Roughly half of patients with ALS die within 2.5 years of symptoms onset, mainly due to respiratory failure, and this illness carries a high economic burden.[@R2] Most cases are sporadic, with onset during middle or old age, and men are affected twice as often as women.[@R1] Apart from age and sex, there are few known risk factors.[@R2]

Similar to several other neurodegenerative diseases, MND is characterised by the accumulation of protein aggregates within vulnerable neurons.[@R1] The glymphatic system of the brain is a major pathway for the removal of toxic substances within the cerebrospinal and interstitial fluids. Its function is similar to that of the lymphatic system in the rest of the body, and glymphatic flow is increased during deep sleep.[@R4] Sleep disruption is linked, for example, to Alzheimer's disease, possibly through reduced clearance of amyloid-beta,[@R5] a protein that accumulates in the brains of patients with Alzheimer's disease. Sleep disruption may also be a risk factor for MND,[@R4] but this association has not been previously investigated.

Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms is a common, age-related disorder in men, with a lifetime prevalence of about 26%.[@R7] Nocturia, defined as two or more voids per night, causes sleep deprivation, sleep fragmentation and insomnia.[@R8] Approximately 70% of men with BPH suffer from nocturia.[@R9] In this study, we sought to evaluate whether there was an association between BPH and MND. Since BPH is a common, treatable condition that often interrupts sleep, an increased risk of MND in this population would support a pathogenetic role of sleep disruption in this disorder and could have public health implications.

We used Danish population-based medical and administrative registries with nationwide coverage and long-term follow-up to examine the association of BPH with ALS and other MND. We hypothesised that BPH would be associated with increased risk of these disorders.

Methods {#s2}
=======

Setting and design {#s2a}
------------------

Denmark has a tax-funded healthcare system, with universal access to general practice and hospital-based care.[@R10] Residents are assigned a unique personal identification number in the Danish Civil Registration System at birth or immigration. This number permits accurate patient-level linkage of data from all Danish registries.[@R10]

BPH cohort {#s2b}
----------

We used the Danish National Patient Registry (DNPR) to identify a cohort of all men with a first-time diagnosis of BPH, seen as inpatients or outpatients in Danish hospitals between 1 January 1980 and 30 November 2013 (the BPH cohort). The DNPR has recorded all inpatient diagnoses and procedures since 1977 and all outpatient clinic visits and emergency room visits since 1995.[@R11] Diagnoses in the DNPR were coded according to the *International Classification of Diseases*, 8th revision (ICD-8) from 1977 to 1993 and 10th revision (ICD-10) since 1994.[@R11] The index date was the date of BPH diagnosis.

General population comparison cohort {#s2c}
------------------------------------

Using the Danish Civil Registration System, we assembled a matched general population comparison cohort of men who were alive and without a diagnosis of BPH or ALS or other MND at the index date of the corresponding patient with BPH. From this pool, we randomly sampled, with replacement, up to five men for each man with BPH, matching on year of birth (the general population comparison cohort).

Outcomes {#s2d}
--------

The outcome of interest was incident MND, based on first-time inpatient diagnoses (from 1980 onwards) or outpatient hospital diagnoses (from 1995 onwards) in the DNPR.

Covariables {#s2e}
-----------

Components of the metabolic syndrome are associated with risks of both BPH[@R12] and MND[@R14] and might therefore act as confounders or as their markers. We used inpatient and outpatient DNPR records to identify diagnoses of diabetes, obesity, hypertension and hyperlipidaemia before the index date among the members of both cohorts. Diagnostic codes used in this study are given in [table 1](#T1){ref-type="table"}.

###### 

*International Classification of Diseases* codes used in the study

  Diagnosis                                                      ICD-8 codes   ICD-10 codes
  -------------------------------------------------------------- ------------- ----------------
  Benign prostatic hyperplasia                                   600           N40.9
  Amyotrophic lateral sclerosis and other motor neuron disease   348           G12.2
  Diabetes                                                       249, 250      E10, E11
  Obesity                                                        277           E65-E68
  Hypertension                                                   400--404      I10-I15, I67.4
  Hyperlipidaemia                                                249, 279.00   E78

ICD-8, *International Classification of Diseases*, 8th edition; ICD-10, *International Classification of Diseases*, 10th edition.

Statistical analyses {#s2f}
--------------------

We characterised the BPH cohort and the general population comparison cohort with respect to age, index year and specified comorbidities. We followed all men from their index dates until the diagnosis of MND, emigration, death or 30 November 2013, and we calculated incidence rates of MND per 1000 person-years in each cohort. We used Cox proportional-hazards regression analysis to compute HRs and associated 95% CIs for MND, comparing men with BPH with men in the general population comparison cohort, while controlling for age and calendar time by study design. In the regression model, we adjusted for diagnoses of diabetes, obesity, hypertension and hyperlipidaemia. We constructed cumulative incidence curves, accounting for the competing risk of death.

We assessed period effects in stratified analyses according to calendar period of BPH diagnosis (before 1994, ICD-8 coding; 1994 and later, ICD-10 coding). We calculated the risk of MND during follow-up of up to 34 years and also during follow-up times of 0--2, \>2--10 and \>10--34 years. The proportionality-of-hazards assumption was deemed fulfilled by inspection of log-log plots in each follow-up interval and in both intervals combined.

Bias analysis {#s2g}
-------------

To test the robustness of the results, we conducted a bias analysis. This study was based on patients with a first-time diagnosis of BPH made during an inpatient or outpatient hospital encounter. However, patients treated solely by their general practitioners are not captured in the DNPR. For this analysis, we assumed that such patients might account for 60% of the total BPH population. Also, we recognised that a few patients diagnosed with BPH in the DNPR may not have BPH. This potential misclassification of BPH status would be non-differential with respect to later MND status but could have diluted the observed association. Therefore, our bias analysis assumed a 40% sensitivity and a 90% specificity for a diagnosis of BPH in the DNPR.

All statistical analyses were performed using SAS V.9.4.

Patient involvement {#s2h}
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for the design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. We have no plans to disseminate results of the research to study participants or relevant patient communities.

Results {#s3}
=======

BPH and MND {#s3a}
-----------

Between 1 January 1980 and 30 November 2013, the prevalence of BPH was 10.8% among Danish men aged 50 years and older, based on 221 978 first-time DNPR diagnoses from an at-risk cumulative population of 2 057 854 men. A total of 223 131 men (1 752 270 person-years at risk) had a first-time diagnosis of BPH, after excluding 103 men with BPH and a diagnosis of ALS or other MND before the index date ([figure 1](#F1){ref-type="fig"}). We identified 1 115 642 (8 774 610 person-years at risk) matched men in the general population comparison cohort ([figure 1](#F1){ref-type="fig"}). The median age was 71.6 (IQR 64.5 to 78.1) years in both cohorts. The median follow-up time was 6.4 (IQR 2.7 to 11.6) years in the BPH cohort and 6.6 (IQR 3.0 to 11.4) years in the general population comparison cohort. [Table 2](#T2){ref-type="table"} shows characteristics of the men in the two cohorts.

![Flowchart for the benign prostatic hyperplasia (BPH) cohort and the general population comparison cohort. MND, motor neuron disease.](bmjopen-2019-030015f01){#F1}

###### 

Descriptive data for men in the benign prostatic hyperplasia cohort and the general population comparison cohort

                    Benign prostatic hyperplasia cohort   General population comparison cohort               
  ----------------- ------------------------------------- -------------------------------------- ----------- -------
  Number            223 131                               100.0                                  1 115 642   100.0
  Age, years                                                                                                 
   \<60             30 305                                13.6                                   151 659     13.6
   60--69           67 920                                30.4                                   339 850     30.5
   70--79           82 734                                37.1                                   413 462     37.1
   80+              42 172                                18.9                                   210 671     18.9
  Index year                                                                                                 
   1980--1994       96 951                                43.5                                   484 752     43.5
   1995--2003       65 893                                29.5                                   329 464     29.5
   2004--2013       60 287                                27.0                                   301 426     27.0
  Diabetes                                                                                                   
   No               210 577                               94.4                                   1 068 017   95.7
   Yes              12 554                                5.6                                    47 625      4.3
  Obesity                                                                                                    
   No               219 348                               98.3                                   1 102 758   98.8
   Yes              3783                                  1.7                                    12 884      1.2
  Hypertension                                                                                               
   No               201 750                               90.4                                   1 037 374   93.0
   Yes              21 381                                9.6                                    78 268      7.0
  Hyperlipidaemia                                                                                            
   No               216 962                               97.2                                   1 089 501   97.7
   Yes              6169                                  2.8                                    26 141      2.3

Over a follow-up period of up to 34 years, we identified 227 cases of ALS or other MND in the BPH cohort (incidence rate 0.13 (95% CI 0.11 to 0.15) per 1000 person-years at risk) and 1094 cases of MND among the matched members of the general population cohort (incidence rate 0.12 (95% CI 0.12 to 0.13) per 1000 person-years at risk) ([table 3](#T3){ref-type="table"}). The median age of diagnosis for MND was 74.7 years (IQR 68.8 to 79.9 years) for men in the BPH cohort and 75.0 years (70.2 to 79.9) in the comparison cohort. The cumulative incidence of MND over 34 years is shown in [figure 2](#F2){ref-type="fig"}. The 34-year risk of MND was 0.16% (95% CI 0.13% to 0.18%) for men in the BPH cohort and 0.16% (95% CI 0.15% to 0.17%) for men in the general population comparison cohort. The adjusted HR was 1.05 (95% CI 0.90 to 1.22). The unadjusted HR was similar to the adjusted (HR 1.04, 95% CI 0.89 to 1.21).

![Cumulative incidence of amyotrophic lateral sclerosis and other motor neuron disease in the benign prostatic hyperplasia cohort and in the general population comparison cohort.](bmjopen-2019-030015f02){#F2}

###### 

Incidence rates, HRs and associated 95% CIs for ALS and other MND, comparing men in the BPH cohort to men in a matched general population cohort

                          ALS and other MND, N   Incidence rate per 1000 person-years (95% CI)   HR (95% CI)           
  ----------------------- ---------------------- ----------------------------------------------- --------------------- ---------------------
  Follow-up period                                                                                                     
  0--34 years                                                                                                          
   Comparison cohort      1094†                  0.12 (0.12 to 0.13)                             Reference             Reference
   BPH cohort             227†                   0.13 (0.11 to 0.15)                             1.04 (0.89 to 1.21)   1.05 (0.90 to 1.22)
  0--2 years                                                                                                           
   Comparison cohort      246                    0.12 (0.11 to 0.14)                             Reference             Reference
   BPH cohort             57                     0.14 (0.11 to 0.18)                             1.18 (0.89 to 1.58)   1.20 (0.90 to 1.61)
  \>2--10 years                                                                                                        
   Comparison cohort      570                    0.12 (0.11 to 0.13)                             Reference             Reference
   BPH cohort             117                    0.12 (0.10 to 0.15)                             1.07 (0.87 to 1.32)   1.08 (0.88 to 1.33)
  \>10--34 years                                                                                                       
   Comparison cohort      278                    0.15 (0.13 to 0.17)                             Reference             Reference
   BPH cohort             53                     0.13 (0.10 to 0.17)                             0.82 (0.58 to 1.15)   0.82 (0.58 to 1.16)
  Year of BPH diagnosis                                                                                                
  1980--1993                                                                                                           
   Comparison cohort      479                    0.11 (0.10 to 0.12)                             Reference             Reference
   BPH cohort             103                    0.12 (0.10 to 0.15)                             1.07 (0.85 to 1.35)   1.06 (0.84 to 1.34)
  1994--2013                                                                                                           
   Comparison cohort      615                    0.13 (0.12 to 0.15)                             Reference             Reference
   BPH cohort             124                    0.14 (0.11 to 0.16)                             1.02 (0.83 to 1.25)   1.03 (0.84 to 1.26)

\*Adjusted for diagnoses of diabetes mellitus, obesity, hypertension and hyperlipidaemia.

†For ALS and other MND, the most common ICD-8 diagnosis was ALS (156 in the comparison cohort, 42 in the BPH cohort), and the most common ICD-10 diagnosis was MND (763 in the comparison cohort, 149 in the BPH cohort). Other ICD-8 diagnoses in these cohorts were other and unspecified MND (37), progressive bulbar paralysis (20), progressive spinal paralysis (10) and other progressive muscular atrophy (2). Other ICD-10 diagnoses were ALS (129), progressive bulbar paralysis (8), progressive spinal paralysis (2), Duchenne-Aran muscular atrophy (2) and progressive spinal muscular atrophy (1).

ALS, amyotrophic lateral sclerosis; BPH, benign prostatic hyperplasia; ICD-8, *International Classification of Diseases*, 8th edition; ICD-10, *International Classification of Diseases*, 10th edition; MND, motor neuron disease.

After 10 years of follow-up, men with BPH had a similar risk of ALS or other MND when compared with men in the general population comparison cohort ([table 3](#T3){ref-type="table"}). When stratified by year of BPH diagnosis, we found similar risks for men diagnosed with BPH during 1980--1993 and for men diagnosed during 1994--2013 ([table 3](#T3){ref-type="table"}).

Bias analysis {#s3b}
-------------

The bias analysis that considered misclassification of the exposure and outcome yielded an unadjusted HR of 1.10 (95% CI 0.76 to 1.60), similar to the HR found in our primary analysis.

Discussion {#s4}
==========

In this nationwide, population-based cohort study, we did not find an association between BPH and ALS and other MND during follow-up of up to 34 years. The association was notably absent in the follow-up period of 10 to 34 years, when prolonged nocturia and sleep disruption from BPH might be expected to have the greatest effect on disease risk. Our findings thus do not support the hypothesis that BPH increases the risk of MND. These results imply that sleep disruption during middle age and older age linked to BPH does not substantially increase the risk of this neurodegenerative disorder. This research involved inhabitants of a developed country where economic and health disparities are relatively low, but the observed association between BPH and MND should be similar in other settings.

MND is characterised by the death of motor neurons, preceded by the accumulation of protein aggregates within these cells.[@R1] Proteins and other wastes are removed from the central nervous system in part via the glymphatic system, primarily during sleep. The role of sleep disruption has been best studied in relation to Alzheimer's disease pathogenesis.[@R5] The glymphatic system entails the influx of cerebrospinal fluid along the Virchow-Robin periarterial spaces driven by pulsations generated by arterial smooth muscle cells, flow through the basal lamina surrounding capillaries, the rapid interchange of cerebrospinal fluid and interstitial fluid in the perivenous space, and efflux through the cervical lymph system.[@R4] Our study was designed to investigate whether BPH---a common medical condition with the propensity to disrupt sleep on a chronic basis---is associated with the risk of MND. Our null results fail to support this association.

Strengths and limitations of the study {#s4a}
--------------------------------------

Our study has important strengths. We derived risk estimates from a population-based cohort study in a setting with a national health service and universal access to healthcare, which largely removed referral and diagnostic bias. Other strengths of this research include the large sample size, longitudinal design, prospective and routine accumulation of the data, and complete follow-up.

There are also limitations. Although most men with BPH suffer from nocturia,[@R9] which in turn leads to sleep deprivation and sleep fragmentation,[@R8] the correspondence between BPH and sleep disturbance is imperfect. Also, MND registration by hospital codes may be subject to misclassification. A Danish validation study estimated that 88% of patients coded with MND have ALS (68%) or another MND (20%), 8% have Parkinson's disease and 4% have no final diagnosis.[@R16] Whereas the validity of a BPH diagnosis in our population is unknown, we would expect some men in the general population comparison cohort to have undiagnosed BPH. Outpatient diagnoses by general practitioners are not captured in the DNPR, although lower urinary tract symptoms would presumably be less severe for men diagnosed solely by general practitioners and nocturia less common. Among Danish men aged 50 years and older, the 10.8% prevalence of BPH is similar to that reported in the Third National Health and Nutrition Examination Survey[@R17] but lower than that in some other representative cohorts.[@R18] However, our bias analysis showed robust results after correction for potential exposure misclassification. Nonetheless, misclassification of BPH or MND could dilute our HR estimates, and we could have failed to detect a modest association, if present.

MND is itself associated with poor sleep quality.[@R19] Although sleep disturbance caused by MND might in some instances precede a diagnosis of MND and perhaps increase the likelihood of BPH diagnosis, MND is not known to have a long presymptomatic phase, and risk estimates were not elevated during follow-up intervals of \>2--10 or \>10--34 years. We adjusted our estimates for individual diagnoses related to the metabolic syndrome, which may be associated with both BPH and MND. Physical activity is a well-known but controversial risk factor for ALS.[@R2] We were unable to adjust for this directly, but we adjusted for obesity, which in turn is linked to physical activity. We are unaware of other shared risk factors, but as in any observational study, our results could be affected by unrecognised confounding.

Comparison with other studies {#s4b}
-----------------------------

We are unaware of other studies that have examined the relation between sleep disruption and ALS and other MND.

Implications and conclusions {#s4c}
----------------------------

We found no evidence of an increased risk of ALS and other MND among men with diagnosed BPH compared with men from the general population. This finding implies that sleep disruptions resulting from nocturnal awakenings in middle-age and older men with BPH are not substantially associated with risk of MND. However, several factors could have biased associations towards the null. The validity of a BPH diagnosis in the Danish population is not known; some men in the general population comparison cohort may have had undiagnosed BPH; and some men diagnosed with MND may have had some other disorder. Estimates from our bias analysis, however, showed results similar to those of our primary analysis. Future studies should examine other causes of sleep disruption in relation to MND risk in both men and women.

Supplementary Material
======================

###### Reviewer comments

###### Author\'s manuscript

**Contributors:** TTS and VWH conceived and designed the study. EH-P performed the statistical analyses. TTS prepared the first draft of the article. TTS, EH-P, MN, VE and VWH contributed substantially to reviewing and interpreting data and to critically appraising the draft article for content, accuracy and integrity. All authors approved the final submitted version. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Funding:** The study was supported by the Program for Clinical Research Infrastructure (PROCRIN), established by the Lundbeck Foundation and the Novo Nordisk Foundation. VWH received support from the National Institutes of Health grant P50 AG047366.

**Competing interests:** None declared.

**Ethics approval:** The study was approved by the Danish Data Protection Agency (record no. 1-16-02-1-08).

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing statement:** Data may be obtained from a third party and are not publicly available.

**Patient consent for publication:** Not required.
